s6y

Dare Bioscience, Inc.

Ticker
DARE
CIK
1401914
Industry
Pharmaceutical Preparations
Formerly
Cerulean Pharma Inc., Tempo Pharmaceuticals Inc

Financials 55

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025
  7. 10-Q Quarterly Report for period ending Mar 31, 2025
  8. 10-K Annual Report for period ending Dec 31, 2024
  9. 10-Q Quarterly Report for period ending Sep 30, 2024
  10. 10-Q Quarterly Report for period ending Jun 30, 2024

All 55 financials filings

News 225

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 225 news filings

Ownership 285

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 285 ownership filings

Prospectus 69

  1. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  2. S-1 General form of registration statement for all companies including face-amount certificate companies
  3. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  4. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  5. 1-A POS Post-qualification amendment to a 1-A offering statement
  6. 1-A/A Offering statement under Regulation A
  7. 1-A Offering statement under Regulation A
  8. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  9. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  10. S-1 General form of registration statement for all companies including face-amount certificate companies

All 69 prospectus filings

Proxies 49

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEF 14A Definitive proxy statements
  3. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  4. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  5. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  6. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  7. DEF 14A Definitive proxy statements
  8. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  9. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  10. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.

All 49 proxies filings

Other 100

  1. 144 Filing for proposed sale of securities under Rule 144
  2. SCHEDULE 13G/A
  3. EFFECT Notice of Effectiveness
  4. SCHEDULE 13G
  5. SCHEDULE 13G
  6. D Exempt (Private) Offering
  7. 253G2 Reflects information that constitutes a substantive change from or addition to the information set forth in the last offering circular
  8. 253G2 Reflects information that constitutes a substantive change from or addition to the information set forth in the last offering circular
  9. 253G2 Reflects information that constitutes a substantive change from or addition to the information set forth in the last offering circular
  10. ARS Annual report to security holders

All 100 other filings